newsfilter
← Latest News
PR Newswire·

MIRAGE Phase III Randomized Controlled Trial Demonstrates Superiority of MRIdian® MRI-Guidance in Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer

Final outcomes comparing acute grade ≥2 genitourinary toxicity following MRI- vs. CT-guided prostate SBRT presented at ASTRO 2022 DENVER, Oct. 27, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) announced today that the